[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Korro Bio Inc (KRRO)

Korro Bio Inc (KRRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,928
  • Shares Outstanding, K 14,726
  • Annual Sales, $ 6,390 K
  • Annual Income, $ -117,260 K
  • EBIT $ -83 M
  • EBITDA $ -79 M
  • 60-Month Beta 3.04
  • Price/Sales 29.74
  • Price/Cash Flow N/A
  • Price/Book 1.80

Options Overview Details

View History
  • Implied Volatility 144.04% (+0.20%)
  • Historical Volatility 58.62%
  • IV Percentile 60%
  • IV Rank 29.84%
  • IV High 316.82% on 02/13/26
  • IV Low 70.56% on 12/11/25
  • Expected Move (DTE 16) 1.96 (16.04%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 1.59
  • Today's Open Interest 709
  • Open Int (30-Day) 1,067
  • Expected Range 10.28 to 14.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.25
  • Number of Estimates 6
  • High Estimate $-0.93
  • Low Estimate $-1.81
  • Prior Year $-1.92
  • Growth Rate Est. (year over year) +34.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.22 +19.77%
on 08/03/26
14.19 -13.71%
on 08/19/26
+1.87 (+18.03%)
since 07/31/26
3-Month
9.76 +25.41%
on 07/31/26
15.55 -21.29%
on 07/06/26
-0.69 (-5.34%)
since 06/01/26
52-Week
5.20 +135.19%
on 12/02/25
55.89 -78.10%
on 10/16/25
-10.84 (-46.97%)
since 08/29/25

Most Recent Stories

More News
Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform...

KRRO : 12.24 (-2.00%)
Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform...

KRRO : 12.24 (-2.00%)
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ® ) platform...

KRRO : 12.24 (-2.00%)
Korro to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform...

KRRO : 12.24 (-2.00%)
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1...

KRRO : 12.24 (-2.00%)
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the...

KRRO : 12.24 (-2.00%)

Business Summary

Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 13.03
2nd Resistance Point 12.83
1st Resistance Point 12.54
Last Price 12.24
1st Support Level 12.04
2nd Support Level 11.84
3rd Support Level 11.55

See More

52-Week High 55.89
Fibonacci 61.8% 36.53
Fibonacci 50% 30.55
Fibonacci 38.2% 24.57
Last Price 12.24
52-Week Low 5.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.